The results of the palliative cohort of the SORAMIC study indicate that there is no confirmed clinical advantage to combining SIRT with standard sorafenib, but a subgroup analysis hints at benefit in certain patient groups. | Read More
The FDA has approved a combination immunotherapy to treat intermediate- or poor-risk advanced renal cell carcinoma. | Read More
CIO included several featured abstracts, and we had the opportunity to talk in more detail with one of the authors. | Read More
The researchers wanted to curate empiric evidence to help guide the clinical choice of ablation modality, | Read More
Timothy Clark, MD, gives tips for conventional TACE in this Craftsman's Corner session from CIO. | Read More

Spotlight

CIO included several featured abstracts, and we had the opportunity to talk in more detail with one of the authors.
Timothy Clark, MD, gives tips for conventional TACE in this Craftsman's Corner session from CIO.
Alda Tam, MD, comments on the current role of biopsy, as well as opportunities for innovation in the near future.